ERBB2 and breast cancer: Therapeutic approaches are still currently largely based on clinical and pathological BC features, mostly on the presence or absence of targets like the hormone receptors or the Human Epidermal growth factor Receptor 2 (HER2) (13), and they are not yet tailored to individual patients.